Please assess the completion status of the following clinical trial:

Trial Title: 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes,~* Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1,~* HbA1c \>6.5% and ≤10.0%~Exclusion Criteria:~* Type 1 diabetes,~* history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,~* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: EXPERIMENTAL): None
- Glipizide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).